Home > News > Detailed Positive ABRAXANE Phase III Data Released
December 8th, 2003
Detailed Positive ABRAXANE Phase III Data Released
American Pharmaceutical Partners, Inc. and ABRAXIS Oncology, the proprietary drug division of APP, today announced positive results of the randomized, controlled Phase III clinical trial in patients with metastatic breast cancer comparing the investigational product ABRAXANE(TM) to the CremophorŽ solvent-based TAXOLŽ. Patients with metastatic breast cancer receiving the solvent-free nanoparticle paclitaxel, ABRAXANE achieved almost a doubling of the tumor response rate when compared to those patients receiving Bristol-Myers Squibb's TAXOLŽ.
Speed at its limits September 30th, 2014
Ad-REIC vaccine: A magic bullet for cancer treatment September 30th, 2014
New Topical Hemostatic Agent: Neutral Self-Assembling Peptide Hydrogel September 30th, 2014
A Heartbeat Away? Hybrid "Patch" Could Replace Transplants: TAU researcher harnesses gold nanoparticles to engineer novel biocompatible cardiac patch September 30th, 2014